Cargando…

Percutaneous radiofrequency ablation with contrast-enhanced ultrasonography for solitary and sporadic renal cell carcinoma in patients with autosomal dominant polycystic kidney disease

BACKGROUND: The aim of this study was to assess the functional and oncologic outcomes of percutaneous radiofrequency ablation (RFA) with contrast-enhanced ultrasonography (CEUS) for renal cell carcinoma in patient with autosomal dominant polycystic kidney. METHODS: We performed a retrospective revie...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Linfeng, Rong, Yang, Wang, Wei, Lian, Huibo, Gan, Weidong, Yan, Xiang, Li, Xiaogong, Guo, Hongqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962510/
https://www.ncbi.nlm.nih.gov/pubmed/27460786
http://dx.doi.org/10.1186/s12957-016-0916-3
_version_ 1782444851929808896
author Xu, Linfeng
Rong, Yang
Wang, Wei
Lian, Huibo
Gan, Weidong
Yan, Xiang
Li, Xiaogong
Guo, Hongqian
author_facet Xu, Linfeng
Rong, Yang
Wang, Wei
Lian, Huibo
Gan, Weidong
Yan, Xiang
Li, Xiaogong
Guo, Hongqian
author_sort Xu, Linfeng
collection PubMed
description BACKGROUND: The aim of this study was to assess the functional and oncologic outcomes of percutaneous radiofrequency ablation (RFA) with contrast-enhanced ultrasonography (CEUS) for renal cell carcinoma in patient with autosomal dominant polycystic kidney. METHODS: We performed a retrospective review of five patients with renal cell carcinoma (RCC) in autosomal dominant polycystic kidney disease (ADPKD) from January 2009 to December 2014 with a media follow-up of 33 months. The tumors were ablated with Cool-tip RFA system under the guidance of CEUS. Routine follow-up included contrast-enhanced computed tomography/magnetic resonance imaging (CT/MRI) and renal function tests. RESULTS: Media diameter of the treated renal tumors was 3.1 cm (range 1.7–5.2 cm). Initial ablation success rate was 4/5. After over 6 months contrast-enhanced CT/MRI follow-up after RFA, no patients experienced local tumor recurrence. No patients required dialysis in the periprocedural period. Minor complications only developed in two cases. There was no significant difference in estimated glomerular filtration rate (eGFR) between pre- and post-RFA. CONCLUSIONS: Our initial experience of this technique for RCC in ADPKD was favorable with good renal function preservation and oncologic outcomes. It may be a good choice for RCC in ADPKD.
format Online
Article
Text
id pubmed-4962510
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49625102016-07-28 Percutaneous radiofrequency ablation with contrast-enhanced ultrasonography for solitary and sporadic renal cell carcinoma in patients with autosomal dominant polycystic kidney disease Xu, Linfeng Rong, Yang Wang, Wei Lian, Huibo Gan, Weidong Yan, Xiang Li, Xiaogong Guo, Hongqian World J Surg Oncol Research BACKGROUND: The aim of this study was to assess the functional and oncologic outcomes of percutaneous radiofrequency ablation (RFA) with contrast-enhanced ultrasonography (CEUS) for renal cell carcinoma in patient with autosomal dominant polycystic kidney. METHODS: We performed a retrospective review of five patients with renal cell carcinoma (RCC) in autosomal dominant polycystic kidney disease (ADPKD) from January 2009 to December 2014 with a media follow-up of 33 months. The tumors were ablated with Cool-tip RFA system under the guidance of CEUS. Routine follow-up included contrast-enhanced computed tomography/magnetic resonance imaging (CT/MRI) and renal function tests. RESULTS: Media diameter of the treated renal tumors was 3.1 cm (range 1.7–5.2 cm). Initial ablation success rate was 4/5. After over 6 months contrast-enhanced CT/MRI follow-up after RFA, no patients experienced local tumor recurrence. No patients required dialysis in the periprocedural period. Minor complications only developed in two cases. There was no significant difference in estimated glomerular filtration rate (eGFR) between pre- and post-RFA. CONCLUSIONS: Our initial experience of this technique for RCC in ADPKD was favorable with good renal function preservation and oncologic outcomes. It may be a good choice for RCC in ADPKD. BioMed Central 2016-07-26 /pmc/articles/PMC4962510/ /pubmed/27460786 http://dx.doi.org/10.1186/s12957-016-0916-3 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Xu, Linfeng
Rong, Yang
Wang, Wei
Lian, Huibo
Gan, Weidong
Yan, Xiang
Li, Xiaogong
Guo, Hongqian
Percutaneous radiofrequency ablation with contrast-enhanced ultrasonography for solitary and sporadic renal cell carcinoma in patients with autosomal dominant polycystic kidney disease
title Percutaneous radiofrequency ablation with contrast-enhanced ultrasonography for solitary and sporadic renal cell carcinoma in patients with autosomal dominant polycystic kidney disease
title_full Percutaneous radiofrequency ablation with contrast-enhanced ultrasonography for solitary and sporadic renal cell carcinoma in patients with autosomal dominant polycystic kidney disease
title_fullStr Percutaneous radiofrequency ablation with contrast-enhanced ultrasonography for solitary and sporadic renal cell carcinoma in patients with autosomal dominant polycystic kidney disease
title_full_unstemmed Percutaneous radiofrequency ablation with contrast-enhanced ultrasonography for solitary and sporadic renal cell carcinoma in patients with autosomal dominant polycystic kidney disease
title_short Percutaneous radiofrequency ablation with contrast-enhanced ultrasonography for solitary and sporadic renal cell carcinoma in patients with autosomal dominant polycystic kidney disease
title_sort percutaneous radiofrequency ablation with contrast-enhanced ultrasonography for solitary and sporadic renal cell carcinoma in patients with autosomal dominant polycystic kidney disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962510/
https://www.ncbi.nlm.nih.gov/pubmed/27460786
http://dx.doi.org/10.1186/s12957-016-0916-3
work_keys_str_mv AT xulinfeng percutaneousradiofrequencyablationwithcontrastenhancedultrasonographyforsolitaryandsporadicrenalcellcarcinomainpatientswithautosomaldominantpolycystickidneydisease
AT rongyang percutaneousradiofrequencyablationwithcontrastenhancedultrasonographyforsolitaryandsporadicrenalcellcarcinomainpatientswithautosomaldominantpolycystickidneydisease
AT wangwei percutaneousradiofrequencyablationwithcontrastenhancedultrasonographyforsolitaryandsporadicrenalcellcarcinomainpatientswithautosomaldominantpolycystickidneydisease
AT lianhuibo percutaneousradiofrequencyablationwithcontrastenhancedultrasonographyforsolitaryandsporadicrenalcellcarcinomainpatientswithautosomaldominantpolycystickidneydisease
AT ganweidong percutaneousradiofrequencyablationwithcontrastenhancedultrasonographyforsolitaryandsporadicrenalcellcarcinomainpatientswithautosomaldominantpolycystickidneydisease
AT yanxiang percutaneousradiofrequencyablationwithcontrastenhancedultrasonographyforsolitaryandsporadicrenalcellcarcinomainpatientswithautosomaldominantpolycystickidneydisease
AT lixiaogong percutaneousradiofrequencyablationwithcontrastenhancedultrasonographyforsolitaryandsporadicrenalcellcarcinomainpatientswithautosomaldominantpolycystickidneydisease
AT guohongqian percutaneousradiofrequencyablationwithcontrastenhancedultrasonographyforsolitaryandsporadicrenalcellcarcinomainpatientswithautosomaldominantpolycystickidneydisease